US 9,810,696 B2
PGLYRP2 biomarker in idiopathic pneumonia syndrome
Mark Chance, Chagrin Falls, OH (US); Kenneth Cooke, Solon, OH (US); and Daniela Schlatzer, Lakewood, OH (US)
Assigned to Case Western Reserve University, Cleveland, OH (US)
Filed by Case Western Reserve University, Cleveland, OH (US)
Filed on Dec. 15, 2014, as Appl. No. 14/571,067.
Application 14/571,067 is a continuation of application No. 13/375,523, filed on Dec. 1, 2011, granted, now 8,911,960, issued on Dec. 16, 2014.
Claims priority of provisional application 61/182,870, filed on Jun. 1, 2009.
Prior Publication US 2015/0099664 A1, Apr. 9, 2015
Int. Cl. G01N 33/53 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 2333/98 (2013.01); G01N 2800/12 (2013.01); G01N 2800/245 (2013.01); G01N 2800/56 (2013.01)] 3 Claims
1. A method for identifying and treating idiopathic pneumonia syndrome (IPS) progression in a subject following allogeneic hematopoietic stem cell transplantation, the method comprising:
obtaining a biological sample from the subject, wherein the biological sample comprises a sample of blood, plasma, serum, or bronchoalveolar lavage fluid, wherein the subject has received the allogeneic hematopoietic stem cell transplantation;
determining in the biological sample a level of PGLYRP2;
comparing the determined level of PGLYRP2 to a control level prior to transplantation;
identifying the IPS as progressing if the level of PGLYRP2 determined is decreased at least 5% compared to the control level; and
administering a therapeutically effective amount at least one TNF-α inhibitor to the subject with progressive IPS.